The Journal of Pediatrics
Volume 150, Issue 4 , Pages 335-337 , April 2007

B Cell Depletion: On the Rise

  • Claas H. Hinze, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Claas H. Hinze, MD, Cincinnati Children’s Hospital Medical Center, Division of Rheumatology, ML-4010, 3333 Burnet Ave, Cincinnati, OH 45229.
    • ,
  • Alexei A. Grom, MD

Received 27 November 2006 ,Accepted 21 December 2006.

References 

  1. El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, et al. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr. 2007;150:376–382
  2. http://www.ClinicalTrials.gov. (search for Rituximab)
  3. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15:450–454
  4. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50:3580–3590
  5. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581
  6. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613–620
  7. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis. 2006;65:942–945
  8. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–473
  9. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol. 2006;20:915–928
  10. Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematological side effects following rituximab therapy in children. Haematologica. 2006;91(8 Suppl):ECR36
  11. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–2642
  12. Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N. The effects of rituximab treatment during pregnancy on a neonate. Haematologica. 2006;91:1426–1427
  13. Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev. 2005;204:43–54
  14. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006;15:570–576
  15. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2006;[Epub ahead of print]
  16. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, et al. Differential effects on BAFF and APRIL levels in rituximab treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:R167
  17. Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs. 2006;7:464–472

PII: S0022-3476(07)00006-6

doi: 10.1016/j.jpeds.2006.12.050

The Journal of Pediatrics
Volume 150, Issue 4 , Pages 335-337 , April 2007

Article Tools